The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB Number: 3235-0076

Estimated average burden hours per response: 4.00

OMB APPROVAL

Notice of Exempt Offering of Securities

1. Issuer's Identity				_
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001832415	Mountain Cre	est Acquisition Corp II	X Corporation	
Name of Issuer			Limited Partnership	
Better Therapeutics, Inc.			Limited Liability Company	
Jurisdiction of Incorporation/Org	ganization		General Partnership	
DELAWARE				
Year of Incorporation/Organizat	tion		Business Trust	
Over Five Years Ago			Other (Specify)	
X Within Last Five Years (Spe	ecify Year) 2020			
Yet to Be Formed	• ,			
2. Principal Place of Business	and Contact Information			_
Name of Issuer				
Better Therapeutics, Inc.		Ctroot Addrson 2		
Street Address 1 548 MARKET ST. #49404		Street Address 2		
	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
City SAN FRANCISCO	CALIFORNIA	94104	(415) 887-2311	
BANTKANCISCO	CALIFORNIA	74104	(413) 667-2311	
3. Related Persons				
Last Name	First Name		Middle Name	
Karbe	Frank			
Street Address 1	Street Address 2			
548 Market St. #49404				
City	State/Province/Co	ountry	ZIP/PostalCode	
San Francisco	CALIFORNIA		94104	
Relationship: X Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Perry	David			
Street Address 1	Street Address 2			
548 Market St. #49404				
City	State/Province/Co	ountry	ZIP/PostalCode	
San Francisco	CALIFORNIA		94104	
Relationship: X Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Berman	Mark			
Street Address 1	Street Address 2			
548 Market St. #49404				
City	State/Province/Co	ountry	ZIP/PostalCode	
San Francisco	CALIFORNIA		94104	
Relationship: X Executive Offi	icer Director Promoter			

Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Wynholds	Kristin		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: X Executive Officer		,	
Clarification of Response (if Necess			
- Claimedien of Response (ii Nessa			
Last Name	First Name	Middle Name	
Heinen	Mark		
Street Address 1	Street Address 2		
548 Market St. #49404			
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Carmona	Richard	Middle Maille	
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Officer		74104	
Relationship. Executive Officer	A Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Armanino	Andrew		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Lavizzo-Mourey	Risa	Wildale Name	
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
_		74104	
	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Parker	Geoffrey		
Street Address 1	Street Address 2		
c/o Better Therapeutics, Inc.	548 Market St. #49404		
City	State/Province/Country	ZIP/PostalCode	
San Francisco	CALIFORNIA	94104	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	

Granger Street Address 1 c/o Better Therapeutics, Inc. City San Francisco Relationship: Executive Officer X Direction of Response (if Necessary):	Street Address 2 548 Market St. #49404 State/Province/Country CALIFORNIA ector Promoter	ZIP/PostalCode 94104	
4. Industry Group			
Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other	
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s)	Aggregate Net Asset Va No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,00 \$25,000,001 - \$50,00 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable S) Claimed (select all that apply)	sset Value 0,000 00,000 000,000	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)		any Act Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13) Section 3(c)(14)	

7. Type of Filing				
X New Notice Date of First Sale 2023-04-06 First Sale Yell Amendment	t to Occur			
8. Duration of Offering				
Does the Issuer intend this offering to last more than one year?	Yes X No			
9. Type(s) of Securities Offered (select all that apply)				
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other Other (describe)			
10. Business Combination Transaction				
Is this offering being made in connection with a business combinenger, acquisition or exchange offer?	nation transaction, such as a Yes X No			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor \$0 US	D			
12. Sales Compensation				
Recipient	Recipient CRD Number None			
Chardan Capital Markets LLC	120128			
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None			
None	None			
Street Address 1 17 State Street, Suite 2130	Street Address 2			
City	State/Province/Country	ZIP/Postal Code		
New York	NEW YORK	10004		
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	X Foreign/non-US			
ARKANSAS				
CALIFORNIA				
FLORIDA NEW YORK				
TOTAL TOTAL				
Recipient	Recipient CRD Number None			
Brookline Capital Markets, a division of Arcadia Securities, LLC	44656			
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None			
None	None			
Street Address 1 1370 Avenue of the Americas, 29th Floor	Street Address 2			
City	State/Province/Country	ZIP/Postal Code		
New York	NEW YORK	10019		
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	X Foreign/non-US			
CALIFORNIA				
FLORIDA NEW YORK				
NEW YORK				
13. Offering and Sales Amounts				
Total Offering Amount \$6,500,001 USD or Indefinite				

USD

Total Amount Sold

Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):
Private placement of shares of common stock at a price of \$0.825 per share.
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$325,000 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

\$6,500,001

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Better Therapeutics, Inc.	/s/ Frank Karbe	Frank Karbe	Chief Executive Officer	2023-04-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D. States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.